Navigation Links
Structural Genomics Consortium releases 1,000th protein structure
Date:9/28/2010

The Structural Genomics Consortium (SGC), an international public-private partnership that aims to determine three dimensional structures of medically important proteins, announced today the release into the public domain of its 1000th high resolution protein structure.

The 1000th structure known as JmjD2C belongs to a class of proteins involved in epigenetic signalling, a key research area for the SGC. Epigenetics is the study of inherited changes in gene expression caused by proteins such as JmjD2C which 'switch' genes on or off. It is believed that a better understanding of epigenetics could lead to new treatments for a wide variety of diseases including cancer, diabetes, obesity and many psychiatric diseases.

"JmjD2C is already known to play a key a role in the maintenance of self renewal in stem cells as well as roles in cancer," says Professor Udo Oppermann of SGC Oxford, who led the team solving the 1000th structure. "Now that its 3D structure is in the public domain, we hope that this will spur other scientists to investigate its functions more deeply and understand more clearly its role in epigenetics."

"This milestone reinforces the advantages of open-innovation partnerships between the public and private sectors," says Dr Aled Edwards the SGC Chief Executive. "We're extremely proud of this achievement and the efforts of our co-workers and their collaborators around the world."

Formed in 2004, the SGC comprises 180 scientists at labs at the Universities of Oxford and Toronto, and the Karolinska Institutet in Stockholm. The international collaboration is supported by public and private sector funding. All research output is made available to the research community free from restriction on use and protein structures are deposited in the Protein Data Bank (PDB). In 2009, the SGC contributed nearly a third of all new human proteins structures deposited in the PDB, and a similar fraction of protein structures from pathogenic protozoa.

The vast amount of structural information generated by the SGC provides insights into molecular function and is expected to have a great impact on human health by providing a structural framework for the rational chemical design of new or improved drugs that can inhibit or enhance protein function.

"The SGC is providing an incredibly valuable resource to the entire biomedical research community," says Professor Ray Stevens, Department of Molecular Biology and Chemistry at The Scripps Research Institute in La Jolla, USA. "Its systematic approach targeting entire protein families, such as protein kinases and other important as well as potential drug target classes, has yielded data that will be very helpful for investigators working to understand further the roles these proteins play in key biological functions. I applaud them for their efforts and accomplishments."

Since its launch, the SGC has identified and deposited in the PDB key protein structures involved in all aspects of cellular function and linked to diseases such as cancer, inflammation, diabetes, neurological disorders and infection. Many of the structures have also been published in scientific articles. Most publications, totalling over 250, are the result of collaborative projects with other scientists utilizing the structural information; the SGC is involved in more than 200 active collaborations with academics around the world.

Dr Alan Schafer, Director of Science Funding at the Wellcome Trust, comments: "The SGC has achieved a remarkable milestone in depositing its thousandth structure in the public domain. This success demonstrates the value of the public-private partnership model avoiding duplication of effort and allowing maximum benefit to the whole research community."


'/>"/>

Contact: Craig Brierley
c.brierley@wellcome.ac.uk
44-207-611-7329
Wellcome Trust
Source:Eurekalert  

Related biology news :

1. Pitt/Iowa team finds cellular structural molecule can be toxic: Makes pneumonia worse
2. Structural defects precede functional decline in heart muscle
3. University of Nevada professor studies structural basis for autism disorders
4. National Science Foundation awards grant to Oklahoma structural biology group
5. National Science Foundations awards grant to Oklahoma structural biology group
6. Structural biology scores with protein snapshot
7. NIH expands key pharmacogenomics resource
8. Paper offers new insights into the genomics of speciation
9. Symposium spotlights new paradigms in genomics, celebrates AIDS-fighting drug at 25 years
10. MIT student inventor honored for transformative work in genomics and linguistics
11. The impact of genomics
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Structural Genomics Consortium releases 1,000th protein structure
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis zum Jahr 2018 ... mehr als 50 Vertretern aus verschiedenen Branchen wurde aber klar, ... Prognose zu realisieren. ... Zu den Schwierigkeiten für Biobanking-Profis ... die Biobank, die Implementierung Zeit sparender Technologien, ein besseres ...
(Date:2/14/2017)... 2017  Wake Forest Baptist Medical Center today announced Julie ... executive officer (CEO). Freischlag joins the medical center on ... , M.D., who last year announced that he would ... after leading it since 2008.   As ... Forest Baptist,s academic health system, which includes Wake Forest ...
(Date:2/13/2017)... Feb. 13, 2017 Former 9/11 Commission border ... Committee, Janice Kephart of Identity Strategy Partners, ... Donald Trump,s "Executive Order: Protecting the Nation From ... 2017):  "As President Trump,s ,Travel Ban, Executive ... now essentially banned the travel ban, it is important ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... , March 22, 2017  UBM and ... to announce their extended partnership and the third ... headlined by the 21 st Annual MassMEDIC ... taking place May 3-4, 2017. ... Technology Association (ADVAMED) President and CEO, Scott ...
(Date:3/22/2017)... 22, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... www.oramed.com ), a clinical-stage pharmaceutical company ... systems, announced today that Dr. Miriam Kidron ... presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing ... Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... New York , March 22, 2017 ... is largely fragmented, states a research report by Transparency ... S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted ... in 2015. The prominent players in this market are ... expand their product portfolio, which is likely to lead ...
(Date:3/22/2017)... /PRNewswire/ - FACIT announced a seed stage investment ... start-up created by FACIT focused on developing a ... with non-dilutive capital, achieves a targeted $3.0M financing ... Propellon to accelerate the nomination of a candidate ... entering a strategic partnership for clinical trials in ...
Breaking Biology Technology: